Sarcopenia as a Predictor of Prognosis in Early Stage Ovarian Cancer

Chae, Su Hyun; Lee, Chulmin; Yoon, Sang Hee; Shim, Seung‐Hyuk; Kim, Soo Nyung; Chung, Sochung; Lee, Ji Young

doi:10.3346/jkms.2021.36.e2

Cited by 12 publications

(13 citation statements)

References 39 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The third lumbar spine SMI is widely used for nutritional assessment and in the assessment of tumor prognosis. However, there is no uniform standard cut-off value (37). Staley, using SMI 41 as the cutoff value, evaluated 201 patients with epithelial ovarian cancer and found that sarcopenia was not associated with poor survival outcomes or chemotherapy toxicity.…”

Section: Skeletal Muscle Indexmentioning

confidence: 99%

Progress in Applicability of Scoring Systems Based on Nutritional and Inflammatory Parameters for Ovarian Cancer

Chen

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

Ovarian cancer is a malignancy that seriously endangers women’s health; its case fatality rate ranks first among the gynecological malignancies. The status of nutrition of ovarian cancer patients is related to their prognoses. Thus, it is important to evaluate, monitor, and improve the nutritional status of ovarian cancer patients during their treatment. Currently, there are several tools for examining malnutrition and nutritional assessment, including NRI (nutrition risk index), PG-SGA (patient-generated subjective global assessment), and NRS 2002 (nutritional risk screening 2002). In addition to malnutrition risk examination and related assessment tools, the evaluation of muscle mass, C-reactive protein, lymphocytes, and other inflammation status indicators, such as neutrophils to lymphocytes ratio, lymphocyte-to-monocyte ratio, and C-reactive protein-albumin ratio, is of great importance. The nutritional status of ovarian cancer patients undergoing surgery affects their postoperative complications and survival rates. Accurate evaluation of perioperative nutrition in ovarian cancer patients is crucial in clinical settings. An intelligent nutritional diagnosis can be developed based on the results of its systematic and comprehensive assessment, which would lay a foundation for the implementation of personalized and precise nutritional therapy.

show abstract

Section: Skeletal Muscle Indexmentioning

confidence: 99%

Progress in Applicability of Scoring Systems Based on Nutritional and Inflammatory Parameters for Ovarian Cancer

Chen

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

show abstract

“…Sarcopenia occurs in approximately 50% of advanced cancer patients, being related to malnutrition, inflammation and tumor treatments [ 6 ]. In these patients, it has been demonstrated to be associated with worse outcomes in terms of overall survival (OS) and progression free survival (PFS), and it can be considered as a negative prognostic factor for different types of cancer, regardless of stage or treatment approach [ 7 , 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study

Tenuta

Pandozzi

Sirgiovanni

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: Sarcopenia is a condition characterized by loss of skeletal muscle mass associated with worse clinical outcomes in cancer patients. Data on sarcopenia in patients undergoing immune checkpoint inhibitors (ICI) therapy are still limited. The aim of this prospective observational study was to investigate the relationship between sarcopenia, ICI treatment response and immunological profile, in patients with advanced non-small cell lung cancer (NSCLC). Methods: Forty-seven stage IV NSCLC patient candidates for starting ICI, were enrolled from the Policlinico Umberto I outpatient Oncology. Patients underwent baseline blood test, inflammatory markers, cytokine assessment and body composition with dual-energy X-ray absorptiometry (DXA). Sarcopenia was defined with appendicular skeletal muscle mass over height2 (ASM/heigh2). Results: Overall, 19/47 patients (40.4%) results were sarcopenic. Sarcopenic patients showed significantly shorter PFS than non-sarcopenic ones (20.3 weeks, 95% CI 7.5–33.1 vs. 61 weeks, 95% CI 22.5–99.4, p = 0.047). Specifically, they had an 8.1 times higher risk of progression disease (PD) than non-sarcopenic patients (OR 8.1, 95%, p = 0.011). Conclusions: Sarcopenic patients showed worse PFS and had a higher risk of PD compared to non-sarcopenic ones. Therefore, sarcopenia may reflect the increased metabolic activity of more aggressive tumors, which involves systemic inflammation and muscle wasting and could be considered a negative predictive factor for ICI response.

show abstract

“…A positive trend was also shown for OS, but it was not statistically significant ( n = 5, adjusted HR: 1.27, 95% CI: 0.98; 1.64, p = 0.070, Table 6 ). The study of Chae et al [ 66 ] appeared to be an outlier and was therefore omitted from the analysis, resulting in a reduction in the estimated HR and heterogeneity ( Table 6 , Figure 2 B).…”

Section: Resultsmentioning

confidence: 99%

“… a Study of Chae et al, 2021 was an outlier [ 66 ], b study of Kumar et al, 2016 was an outlier [ 19 ], c study of Inci et al, 2021 was an outlier [ 77 ]. Abbreviations: CI, confidence interval; HR, hazard ratio; I 2 , heterogeneity between studies; n, number of studies included in analysis; OR, odds ratio.…”

Section: Resultsmentioning

confidence: 99%

“… Association of ( A ) body mass index (Kim et al, 2014 [ 49 ], Slaughter et al, 2014 [ 93 ], Fotopoulou et al, 2011 [ 71 ], Zhang et al, 2005 [ 44 ], Aust et al, 2015 [ 59 ], Califano et al, 2013 [ 65 ], Bae et al, 2014 [ 24 ], Orskov et al, 2016 [ 21 ], Pinar et al, 2017 [ 85 ], Kim et al, 2020 [ 50 ], Previs et al, 2014 [ 86 ], Davis et al, 2016 [ 69 ], Kumar et al, 2014 [ 4 ]), ( B ) muscle mass (Chae et al, 2021 [ 66 ], Bronger et al, 2016 [ 63 ], Rutten et al, 2017 [ 89 ], Aust et al, 2015 [ 59 ], Bruno et al, 2021 [ 64 ], Kim et al, 2020 [ 50 ]) and ( C ) muscle density with overall survival Bruno et al, 2021 [ 64 ], Aust et al, 2015 [ 59 ], Ataseven et al, 2018 [ 58 ], Kumar et al, 2016 [ 19 ]. …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Association between Energy Balance-Related Factors and Clinical Outcomes in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis

Stelten

Schofield

Hartman

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: This systematic review and meta-analysis synthesized evidence in patients with ovarian cancer at diagnosis and/or during first-line treatment on; (i) the association of body weight, body composition, diet, exercise, sedentary behavior, or physical fitness with clinical outcomes; and (ii) the effect of exercise and/or dietary interventions. Methods: Risk of bias assessments and best-evidence syntheses were completed. Meta-analyses were performed when ≥3 papers presented point estimates and variability measures of associations or effects. Results: Body mass index (BMI) at diagnosis was not significantly associated with survival. Although the following trends were not supported by the best-evidence syntheses, the meta-analyses revealed that a higher BMI was associated with a higher risk of post-surgical complications (n = 5, HR: 1.63, 95% CI: 1.06–2.51, p = 0.030), a higher muscle mass was associated with a better progression-free survival (n = 3, HR: 1.41, 95% CI: 1.04–1.91, p = 0.030) and a higher muscle density was associated with a better overall survival (n = 3, HR: 2.12, 95% CI: 1.62–2.79, p < 0.001). Muscle measures were not significantly associated with surgical or chemotherapy-related outcomes. Conclusions: The prognostic value of baseline BMI for clinical outcomes is limited, but muscle mass and density may have more prognostic potential. High-quality studies with comprehensive reporting of results are required to improve our understanding of the prognostic value of body composition measures for clinical outcomes. Systematic review registration number: PROSPERO identifier CRD42020163058.

show abstract

Sarcopenia as a Predictor of Prognosis in Early Stage Ovarian Cancer

Cited by 12 publications

References 39 publications

Progress in Applicability of Scoring Systems Based on Nutritional and Inflammatory Parameters for Ovarian Cancer

Progress in Applicability of Scoring Systems Based on Nutritional and Inflammatory Parameters for Ovarian Cancer

Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study

Association between Energy Balance-Related Factors and Clinical Outcomes in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About